Can we learn lessons from the FDA’s approval of aducanumab?

Nature Reviews Neurology, Published online: 17 September 2021; doi:10.1038/s41582-021-00557-xThe FDA recently granted accelerated approval to aducanumab for the treatment of Alzheimer disease. Here, the authors reflect on the events that led to this controversial approval and consider whether any lessons can be learned for the field.

Source: Nature Reviews Neurology - September 17, 2021 Category: Neurology Authors: Kathy Y. Liu Robert Howard Source Type: research